<DOC>
	<DOCNO>NCT02444949</DOCNO>
	<brief_summary>Among head neck tumor , nasopharyngeal carcinoma ( NPC ) high tendency recurrence metastasis . For advanced NPC patient , chemoradiotherapy main way treatment . Currently , chemotherapy cisplatin ( DDP ) combine 5-fluorouracil ( 5-FU ) classic front line therapy NPC . However , abnormal richness angiogenesis tumor blood supply tissue cause radiation therapy often decrease effect radiochemotherapy . Human recombinant vascular endothelial inhibitor ( endostar ) improve sensitivity chemoradiation via selectively inhibit migration endothelial cell formation tumor vessel . Moreover , would induce vascular remodel normalization tumor vasculature , effectively aid delivery oxygen anticancer drug . In sum , antiangiogenesis combination chemoradiotherapy promise way treatment NPC . In study , first-treated patient NPC ( stage Ⅲ Ⅳa ) confirm pathology , patient recurrent metastatic NPC randomly assign two group ( 1:1 ) : trial group ( DDP , 5-FU , endostar sequential intensity modulate radiation therapy ( IMRT ) ) , control group ( DDP，5-FU sequential IMRT ) . Evaluations develop include progression-free survival ( PFS ) , Overall response rate（ORR） , overall survival ( OS ) , adverse effect rate quality life . This research provide evidence evidence-based medicine safety tolerability endostar clinical application endostar NPC treatment .</brief_summary>
	<brief_title>A Trial Endostar Combination With Chemotherapy DF Sequential Intensity Modulated Radiation Therapy Patients With Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Age 18 70 ear ; Eastern Cooperative Oncology Group performance status 01 ; diagnose firsttreated NPC ( Ⅲ/Ⅳa stage ) confirm pathology ; ecurrent metastatic NPC indication chemoradiotherapy ; one measurable lesion least ( accord RECIST guideline , lesion iameter≥20 mm MRI ) ; life expectancy ≥ 12 week ; adequate hematologic , renal , cardiac liver function ; hemameba≥4.0×109/L ; neutrophil≥2.0×109/L ; platelet≥100×109/L ; hemoglobin≥95g/L ; Serum bilirubin , ALT AST ≤1.5 time maximum criterion ; sufficiently understand study situation sign informed consent . allergy intolerance study drug ; receive anticancer therapy ; uncontrolled central nervous system lesion ; dysfunction important organs； history cardiovascular disease ( include congestive heartfailure , uncontrolled arrhythmia , angina pectoris require longterm drug treatment , lular heart disease , myocardial infarction resistant hypertension ) ; pregnancy lactation woman ; protract Infective wound ; history mental illness easy control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>